#1 Clinical Trials Search in Europe

Dapansutrile

Dapansutrile is an investigational drug being studied in clinical trials for its potential to treat a variety of medical conditions. This article explores the ongoing research into dapansutrile’s safety and effectiveness for diseases like gout, heart failure, diabetes, and COVID-19. We’ll examine how this drug works and what the latest clinical trials are revealing about its therapeutic potential.

Table of Contents

What is Dapansutrile?

Dapansutrile, also known as OLT1177 or 3-methanesulfonyl-propionitrile, is a new drug being studied for its potential to treat various inflammatory conditions[2][3]. It is an oral medication that works by targeting a specific part of the immune system involved in inflammation[1].

How Does Dapansutrile Work?

Dapansutrile works by inhibiting a protein complex called NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3)[6]. This protein complex plays a crucial role in triggering inflammation in the body. By blocking NLRP3, dapansutrile can potentially reduce excessive inflammation associated with various diseases[1].

Conditions Treated with Dapansutrile

Dapansutrile is being studied for its potential to treat several inflammatory conditions, including:

  • Schnitzler’s Syndrome: A rare disorder characterized by chronic hives, fever, and bone pain[1].
  • Advanced Melanoma: A type of skin cancer that has spread to other parts of the body[2].
  • Type 2 Diabetes: A chronic condition affecting how the body processes blood sugar[3].
  • Acute Gout Flare: A sudden, severe attack of joint pain and inflammation caused by uric acid crystals[4].
  • Heart Failure: A condition where the heart can’t pump blood effectively[5].
  • COVID-19: The disease caused by the SARS-CoV-2 virus[6].

Current Clinical Trials

Dapansutrile is currently being tested in several clinical trials:

  • A study for Schnitzler’s Syndrome patients to see if dapansutrile can replace their current treatment[1].
  • A trial combining dapansutrile with pembrolizumab (an immunotherapy drug) for advanced melanoma[2].
  • A study in type 2 diabetes patients to assess its effects on blood sugar control and diabetes-related complications[3].
  • A trial for patients experiencing acute gout flares to evaluate its effectiveness in reducing pain and inflammation[4].
  • A study examining the effects of dapansutrile on heart function in patients with heart failure[5].
  • A trial investigating dapansutrile’s potential to treat moderate COVID-19 symptoms and prevent severe complications[6].

How is Dapansutrile Administered?

Dapansutrile is taken orally in the form of capsules or tablets. The dosage and frequency of administration may vary depending on the condition being treated and the specific clinical trial[1][4]. For example:

  • In the Schnitzler’s Syndrome trial, patients take 500 mg twice daily for up to 14 days[1].
  • In the acute gout flare study, patients receive an initial loading dose of 2000 mg, followed by 1000 mg twice daily for 7 days[4].
  • In the heart failure trial, different dosing regimens are being tested, ranging from once daily to four times daily administration[5].

Potential Side Effects

As dapansutrile is still in clinical trials, its full side effect profile is not yet known. The ongoing studies are carefully monitoring patients for any adverse events. Common assessments include:

  • Physical examinations
  • Vital signs (pulse, blood pressure, temperature, respiratory rate)
  • Blood tests to check for changes in blood cell counts and chemistry
  • Electrocardiograms to monitor heart activity
  • Urine tests

These assessments help researchers understand how the drug affects the body and identify any potential side effects[5][6].

Condition Trial Phase Key Outcomes Measured Administration
Acute Gout Flare Phase 2/3 Pain reduction, joint symptoms Oral tablets, twice daily for 7 days
Systolic Heart Failure Phase 1b Safety, exercise capacity, heart function Oral capsules, once to four times daily for 14 days
Type 2 Diabetes Not specified HbA1c levels, fasting glucose Oral tablets, twice daily for 26 weeks
COVID-19 Phase 2 Clinical improvement, inflammatory markers Oral capsules, twice daily for 14 days
Schnitzler’s Syndrome Phase 2 Symptom control, inflammatory markers Oral capsules, twice daily for 14 days

FAQ

  • What is dapansutrile? Dapansutrile is an investigational drug that inhibits NLRP3, a protein involved in inflammation. It is being studied as a potential treatment for various inflammatory conditions.
  • What conditions is dapansutrile being tested for? Clinical trials are exploring dapansutrile's use in conditions like acute gout flares, heart failure, type 2 diabetes, COVID-19, and Schnitzler's syndrome.
  • How is dapansutrile administered? In most trials, dapansutrile is given as oral capsules or tablets, typically taken once or twice daily. The dosage and frequency can vary depending on the specific study.
  • What are the potential benefits of dapansutrile? Researchers hope dapansutrile may reduce inflammation, alleviate symptoms, and improve outcomes in various inflammatory conditions. However, its effectiveness is still being determined through clinical trials.
  • Are there any known side effects of dapansutrile? As dapansutrile is still in clinical trials, its full side effect profile is not yet known. The ongoing studies are carefully monitoring for any adverse events to assess its safety.

Ongoing Clinical Trials on Dapansutrile

  • Study on Dapansutrile for Patients with Type 2 Diabetes Not Well Controlled on Standard Treatment

    Recruiting

    1
    Investigated drugs:
    Belgium France Germany

  • Study of Dapansutrile and Paracetamol for Patients with Acute Gout Flare

    Recruiting

    1 1 1
    Investigated drugs:
    France The Netherlands Spain

Glossary

  • NLRP3: A protein involved in the body's inflammatory response. Dapansutrile works by inhibiting this protein.
  • Cytokine Release Syndrome (CRS): A condition where the immune system releases too many inflammatory proteins called cytokines, potentially causing severe inflammation throughout the body.
  • Gout: A type of arthritis caused by a buildup of uric acid crystals in the joints, leading to sudden attacks of severe pain and swelling.
  • Systolic Heart Failure: A condition where the heart muscle doesn't pump blood as well as it should, often due to weakness of the heart muscle.
  • Type 2 Diabetes Mellitus: A chronic condition affecting how the body processes blood sugar (glucose), often related to insulin resistance.
  • Schnitzler's Syndrome: A rare disease characterized by chronic hives, fever, bone pain, and other symptoms related to abnormal inflammatory responses in the body.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Pharmacodynamics: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Biomarkers: Measurable indicators in the body that can be used to assess the presence or progress of a disease or the effects of a treatment.
  • HbA1c: A blood test that measures average blood sugar levels over the past 2-3 months, commonly used to monitor diabetes control.

References

  1. https://clinicaltrials.gov/study/NCT03595371
  2. https://clinicaltrials.gov/study/NCT04971499
  3. https://clinicaltrials.eu/trial/study-on-dapansutrile-for-patients-with-type-2-diabetes-not-well-controlled-on-standard-treatment/
  4. https://clinicaltrials.eu/trial/study-of-dapansutrile-and-paracetamol-for-patients-with-acute-gout-flare/
  5. https://clinicaltrials.gov/study/NCT03534297
  6. https://clinicaltrials.gov/study/NCT04540120